Vorinostat With or Without Bortezomib in Treating Patients With Refractory or Recurrent Stage IIB, Stage III, or Stage IV Cutaneous T-Cell Lymphoma

Sponsor
European Organisation for Research and Treatment of Cancer - EORTC
Study ID
NCT01386398
Phase
PHASE3
Status
Withdrawn

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • bortezomib — DRUG
  • vorinostat — DRUG
  • laboratory biomarker analysis — OTHER

Study Details

RATIONALE: Vorinostat and bortezomib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. It is not yet known whether vorinostat is more effective when given alone or when given together with bortezomib in treating patients with refractory or recurrent cutaneous T-cell lymphoma. PURPOSE: This randomized phase III trial is studying how well vorinostat works when given alone compared with vorinostat given together with bortezomib in treating patients with refractory or recurrent stage IIB, stage III, or stage IV cutaneous T-cell lymphoma.

Key Dates

Status verified
Jan 2015

Study Design

Enrollment
0 participants (actual)
Allocation
RANDOMIZED
Primary purpose
TREATMENT

Primary Outcome Measure

Progression-free survival

Related Studies